European countries are gradually turning their attention toward cannabis reform as medical and adult-use cannabis steadily become the new status quo in states around the U.S. While Germany gears up to launch its adult-use program next month, Switzerland has embraced an alternative approach in the form of an adult-use cannabis pilot program.

Earlier in March, Swiss officials published the first data from its pilot study in Zürich, offering initial insights on the demand for legal cannabis in the country along with some emerging consumer trends.

The results of the study will be used to determine what, if any, public health implications adult-use cannabis availability might inflict on Switzerland as well as the rest of Europe.

Switzerland is currently running trials in the cities of Lausanne, Zürich, Liestal, Allschwil, Bern, Bienne, and Lucerne, along with the cantons of Basel-Stadt and Geneva.

A First Look at Cannabis Consumers in the Swiss Pilot Program

Regarding the recently shared data on the “ZüriCan” study, a total of 2,100 people are able to take part with 1,928 currently included and eligible to purchase cannabis as part of the study. 

Significantly more men (80.7%) than women (18%) or nonbinary people (1.2%) are taking part. This disparity was predicted, with researchers referencing a country-wide online survey from 2016 that similarly showed the majority of Swiss cannabis consumers were men. The 28-32 age group is also the most frequently represented in the study, with a mean age of 35 years.

The data also takes a closer look at the consumption habits of study participants, with the majority consuming cannabis four or more times a week.

“Participation in the study seems to be particularly attractive for people who consume frequently,” researchers state via translation. “However, people who only use cannabis a few times a month also take part in the study. This will allow us to compare people with different consumption habits in our study.”

Researchers also note that approximately a fourth of participants had evidence of a cannabis use disorder before they had access to the products in the study — confirmed via a screening questionnaire, the Cannabis Use Disorder Identification Test (CUDIT). Researchers note that this trend mirrors other similar studies.

Acknowledging and honing focus on this variable could also prove to be valuable from a research perspective:

“Regulated distribution of cannabis can create a framework that promotes lower-risk cannabis consumption. In particular, cannabis users who have problematic consumption have easier access to advice and treatment services,” authors note. “… The sales staff at the reference points have been specially trained to provide advice and prevention so that individual, targeted advice is possible. Since study participants always buy their study cannabis from the same source, a closer relationship of trust can develop over time, in which problematic developments can also be identified and discussed.”

Product Trends and ‘Promising Insights’

The program originally offered five options, but in December 2023, it expanded to include nine different cannabis products — five flower and four hash products — with varying levels of THC and CBD. Researchers note that study participants have requested “all products,” with a total of approximately 16,500 sales so far and a total of around 140 kg (around 309 lbs) of cannabis products sold in five-gram packs.

The data did not include any further breakdowns surrounding consumer behavior or the popularity of specific products, however.

The European cannabis company Cannavigia is working with the Swiss Federal Office of Public Health on the study, namely to track cannabis sales and provide data on consumption trends through its Cannabis Dispensary System. 

According to Cannavigia Head of Marketing Tobias Viegener, these initial findings are already providing some major insights.

“The initial data from the ‘ZüriCan’ pilot, published this month, reveals promising insights into the regulated cannabis market’s functionality and its acceptance among participants,” he told Forbes. “This level of engagement indicates a positive reception and an effective distribution system, setting a solid foundation for informing future cannabis policy and regulation.”

Another Cannabis Study is Coming to Switzerland Soon

On March 18, officials also shared an announcement of the country’s latest study, which will run for five years and could see as many as 7,500 participants — Switzerland’s largest trial to date. 

The study will also include a comparison group, with consumers continuing to source cannabis through the illicit market, while the other groups located in Winterthur, Schlieren and Horgen will have access to regulated products through participating pharmacies and retail locations.

Cannavigia software will also be used in the recently announced Canton Zürich pilot study. 

According to the Federal Office of Public Health, “The aim of the pilot trial in the canton of Zürich is to investigate the social and economic consequences of legalising recreational cannabis use in Switzerland. In addition, the effects of a self-regulation programme for the prevention of excessive cannabis use are to be studied. This involves a randomised controlled trial (RCT).”

The post Switzerland Shares First Data on ‘ZüriCan’ Adult-Use Cannabis Pilot Study appeared first on High Times.

The post Switzerland Shares First Data on ‘ZüriCan’ Adult-Use Cannabis Pilot Study appeared first on Paradise Found.

In Switzerland, a pilot program called “Züri Can – Cannabis with Responsibility” officially began on Aug. 22 and will run for three years, concluding in 2026. According to Swissinfo, a multilingual news source based in Sweden, participants may purchase cannabis at nine pharmacies and six social clubs, but can only consume them in private rooms, or in one of the designated social clubs.

The study includes 1,200 pre-approved participants (80% of which are men, ranging between 18 to 80 years of age) who are permitted to purchase legal cannabis. In order to apply, these participants were required to meet specific criteria, including living in one of the 12 districts of Zurich, having already consumed cannabis regularly for more than a year, having good knowledge of German, do not work as a professional driver (taxi, bus, etc.) in any capacity, and are not currently pregnant. Although the study is already underway, residents who meet the criteria can still apply for a chance to participate.

Participants are required to select one supply point, or cannabis pharmacy or club, and cannot change it after it is selected. After purchasing cannabis, participants will regularly be sent online surveys to study the impact of cannabis sales, as well as how it affects consumer health. “The trial will have a broad focus to gain data on the effects of different strengths of cannabis, on what helps individuals make informed decisions and on the pros and cons of different models of sale,” said Zurich municipal health department project manager, Barbara Burri.

The pilot program was first announced back in September 2021, but the program was delayed in October 2022 due to “complexity of the project with its differen[t] reference points.” However, the program received a green light earlier this year in March, when the Zurich city government and Zurich University Hospital approved two cultivators to be used for the program: Pure Production and Swissextract.

Pure Production currently offers two concentrates, Sour Pollen and Lemon Resin, for use in the study. “Today marks the start of the sale of cannabis products for the pilot project ‘Züri Can – Cannabis with Responsibility,’” Pure Production published on Instagram. “As proud partners, we’re elated to be part of this groundbreaking initiative. Pure Production AG has the honor to provide two distinct hash products and, in the near future, flower offerings, furthering our commitment to excellence and quality.”

On Swissextract’s website, the company describes its cannabis cultivation operation, which includes 2,500 plants grown in a 1,000 square meter greenhouse). “Three cannabis strains with an ideal cannabinoid and terpene profile were selected for the study: one with the maximum allowable THC content of 20%, one in the mid-range of 12-13%, and one that has a very balanced content of 10% THC and 10% CBD,” Swissextract wrote. The strain names include Cairo Dessert (Fruit Tartar x Sinai), Apricot Mimosa (Mimosa x Purple Apricot), and Wedding Cake (Triangle Kush x Animal Mints).

According to the Zurich study website, new products including Jurassic Gold and Grand Marais concentrates from Pure Production, and Super Lemon Haze and Sour Diesel strains from Swissextract, will become available after fall 2023.

There is also another Swizterland-based study awaiting launch, called SCRIPT (Safer Cannabis Research In Pharmacies), which is expected to begin in fall this year. The SCRIPT program received approval from the Federal Office of Public Health (BAG), the cantonal ethics committee of Bern, and ethics committee of Northwest and Central Switzerland, in May.

The study will be conducted by researchers from the University of Bern and Lucerne, and include the cities of Bern, Lucerne, and Biel. “The aim of the study is to investigate the health and social effects of a strictly regulated, non-profit-oriented sale of cannabis in pharmacies,” said SCRIPT study head Reto Auer. “Our study therefore does not aim to legalize cannabis in the free market—but to be able to address the problems caused by prohibition and the black market and to test possible harm reduction approaches, as well as a strict control of supply and distribution use demand for cannabis.”

As of July, the SCRIPT study has received 1,091 applications to participate. One SCRIPT applicant, referred to as E.S., is a 40-year -old individual who has been consuming since she was a teenager. In an interview with Swissinfo, she explained how cannabis has helped treat her menstrual pain, and is a reliable way to help her relax after work. “As a conscious consumer, I want to be able to decide what kind of cannabis to use,” she said. “Like a wine enthusiast, I want to discover the many varieties without depending on the black market.”

Swissinfo notes that it has taken more than 10 years for the SCRIPT program to finally begin. The last hurdle came in 2021 with the amendment of the Federal Act on Narcotics and Psychotropic Substances, which put regulations in place for scientific studies.

The post Legal Cannabis Pilot Program Officially Launches in Zurich, Switzerland appeared first on High Times.

The post Legal Cannabis Pilot Program Officially Launches in Zurich, Switzerland appeared first on Paradise Found.

The government of Switzerland has approved a plan to legalize the possession and consumption of cannabis in the city of Zurich as part of a three-year pilot program to assess the social and economic impacts of legalizing cannabis. Through the trial, thousands of Zurich residents will be able to purchase cannabis for personal use beginning this summer.

“The trial will have a broad focus to gain data on the effects of different strengths of cannabis, on what helps individuals make informed decisions and on the pros and cons of different models of sale,” said Barbara Burri, a project manager at Zurich’s municipal health department.

The pilot program will allow a test group of up to 2,100 Zurich residents to purchase regulated doses of cannabis for personal use from pharmacies, social clubs and special dispensaries. Researchers have made arrangements for a total of 21 supply points to be located throughout the city. Sales of cannabis for the study are expected to begin at the supply points beginning in August of this year. 

The study’s participants will have the option of a variety of cannabis products with different potencies of THC and CBD. All cannabis products obtained through the pilot program will be organically produced by licensed Swiss companies and lab tested for purity and potency. Prices of cannabis available at the study supply points will be set to reflect prices of the city’s illicit market.

After receiving government approval, two producers—Pure Production AG and Swissextract—will begin cultivating cannabis for the study, according to a report from Forbes. The first harvest of cured cannabis flower is expected to be ready in July, with cannabis concentrates coming to the pilot program’s supply points in October.

Participants in the study, which is being conducted by the Zurich city council in association with the University of Zurich, will be required to answer a questionnaire every six months during the three-year study period. The questionnaire will ask participants about their cannabis consumption habits and the health effects of their cannabis use. 

Study Focuses On the Impacts of Legalization in Zurich

The leaders of the study say that the goal of the pilot program is to determine the conditions under which cannabis legalization in Switzerland can be compatible with “promoting individual and public health and safety,” according to a report from CNBC. Data collected from the trial will be released on a rolling basis beginning next year.

“The idea is to get robust real world evidence that serves policymaking for new [national] regulation on cannabis,” Burri said. 

Researchers conducting the study will compare and contrast the advantages and disadvantages of different cannabis products and supply sources. The study will also assess the current illicit cannabis market in Zurich, with the research focusing on maintaining public health, ensuring public safety and protecting young people from the risks of cannabis use.

Zurich residents interested in participating in the cannabis legalization pilot study can register for the program online. Participants must be active cannabis users at least 18 years old. Pregnant women, professional drivers and those with underlying health conditions are not eligible to participate in the research pilot. Study candidates who show signs of drug dependence or poor health due to drug use are also ineligible.

Public health studies have determined that about a third of adults in Switzerland have tried cannabis. Zurich, the alpine nation’s most populous city with about 420,000 residents, has about 13,000 regular cannabis users, according to research. 

In 2020, the Swiss federal parliament passed a so-called experimental article in the Narcotics Act, which allows studies to be carried out on the regulated sale of cannabis. On May 15, 2021, the amendment to the Narcotics Act went into effect, enabling pilot trials with the controlled sale of cannabis for recreational purposes.

The city of Basel was the first municipality in Switzerland to conduct a pilot study, launched last year with 400 participants. Other pilot studies planned for the Swiss cities of Bern, Lausanne, Geneva, Biel, Thun, Olten and Winterthur will be conducted in the upcoming months.

Malta is the only country in the European Union that has legalized recreational cannabis for personal use, although sales of adult-use cannabis have not been legalized on the tiny island nation in the Mediterranean Sea. Germany will likely be the next EU member to legalize recreational marijuana, with legislation expected from lawmakers soon. The Czech Republic has also announced plans to legalize cannabis for adults, although details of the plan have not yet been released.

Cannabis legalization plans that would allow cultivation for personal use have been proposed by officials in Luxembourg and Belgium. And last month, the Netherlands launched a pilot program for cannabis sales in the cities of Tilburg and Breda.

The post Zurich To Launch Cannabis Legalization Pilot Program appeared first on High Times.

The post Zurich To Launch Cannabis Legalization Pilot Program appeared first on Paradise Found.